


Diagnosing and managing diabetic somatic and autonomic neuropathy

Shazli Azmi, Maryam Ferdousi, Alise Kalteniece, Hamad Al-Muhannadi, Abdulrahman Al-Mohamedi, Nebras H. Hadid, Salah Mahmoud, Harun A. Bhat, Hoda Y. A. Gad, Adnan Khan, Georgios Ponirakis, Ioannis N. Petropoulos, Uazman Alam and Rayaz A. Malik 

Ther Adv Endocrinol Metab

2019, Vol. 10: 1–10

DOI: 10.1177/

2042018819826890

© The Author(s), 2019.
Article reuse guidelines:
sagepub.com/journals-permissions

Abstract: The diagnosis and management of diabetic neuropathy can be a major challenge. Late diagnosis contributes to significant morbidity in the form of painful diabetic neuropathy, foot ulceration, amputation, and increased mortality. Both hyperglycaemia and cardiovascular risk factors are implicated in the development of somatic and autonomic neuropathy and an improvement in these risk factors can reduce their rate of development and progression. There are currently no US Food and Drug Administration (FDA)-approved disease-modifying treatments for either somatic or autonomic neuropathy, as a consequence of multiple failed phase III clinical trials. While this may be partly attributed to premature translation, there are major shortcomings in trial design and outcome measures. There are a limited number of partially effective FDA-approved treatments for the symptomatic relief of painful diabetic neuropathy and autonomic neuropathy.

Keywords: diabetic neuropathy, autonomic neuropathy, diagnosis, treatment

Received: 28 November 2018; revised manuscript accepted: 7 January 2019.

Introduction

Diabetic peripheral neuropathy (DPN) occurs as a consequence of damage to the sensory, autonomic and motor nerves and can present with diverse symptoms and deficits (Table 1). The commonest presentations are those of somatic and autonomic neuropathy, and early diagnosis of these subtypes is recommended.¹ Small-fibre neuropathy can develop in patients with impaired glucose tolerance (IGT),² particularly those who develop type 2 diabetes mellitus (T2DM)³ and it is recommended that patients with peripheral neuropathy should be evaluated for glucose dysmetabolism. However, the methods currently advocated to diagnose DPN, for example, neurological exam, monofilament and vibration sensation, detect moderate-to-severe large-fibre neuropathy, missing early small-fibre neuropathy.⁴ Other causes of neuropathy, including B12 deficiency, and inflammatory neuropathies must be actively sought, as they are potentially treatable.^{5,6} It is generally held that motor problems arise late in diabetic

neuropathy, however recent studies show reduced muscle strength, volume and altered gait in patients with IGT and T2DM.^{7–9} Furthermore, acute-onset severe pain and swelling in a proximal muscle, should also alert the physician to the occurrence of diabetic muscle infarction.¹⁰ There is a threefold to fivefold higher prevalence of cranial¹¹ and peripheral mononeuropathies in patients with diabetes. Carpal tunnel syndrome is the commonest mononeuropathy in patients with diabetes¹² due to increased microangiopathy and vascular endothelial growth factor expression.^{13,14} While bracing and splinting relieve pain, carpal tunnel decompression surgery outcomes are excellent and associated with recovery of neurophysiological function in patients with diabetes.¹⁵

Disease-modifying therapies for DPN

Improved glycaemic control can prevent the progression of diabetic neuropathy in T1DM, but not in T2DM.¹⁶ This surprising result may be attributed to

Correspondence to:
Rayaz A. Malik
Weill Cornell Medicine-
Qatar, Education City,
Doha 24144, Qatar
ram2045@qatar-med.cornell.edu
Shazli Azmi
Maryam Ferdousi
Alise Kalteniece
Institute of Cardiovascular
Sciences, University
of Manchester and
Central Manchester
NHS Foundation Trust,
Manchester, UK
Hamad Al-Muhannadi
Abdulrahman Al-Mohamedi
Nebras H. Hadid
Salah Mahmoud
Harun A. Bhat
Hoda Y. A. Gad
Adnan Khan
Georgios Ponirakis
Ioannis N. Petropoulos
Weill Cornell Medicine-
Qatar, Qatar Foundation,
Doha, Qatar
Uazman Alam
Department of Eye and
Vision Science, University
of Liverpool, Liverpool, UK

Table 1. Presentations of diabetic neuropathy.

Diabetic sensorimotor polyneuropathy
Predominantly small-fibre neuropathy Predominantly large-fibre neuropathy Mixed small and large-fibre neuropathy (commonest)
Atypical neuropathy
Isolated cranial neuropathy (III, IV, VI, VII) Mononeuropathy (ulnar, median, peroneal)
Radiculopathy
Lumbosacral radiculoplexus neuropathy (amyotrophy) Cervical/thoracic radiculopathy
Motor neuropathy
Reduced muscle volume and strength Muscle infarction

late and less effective lowering of glucose in patients with T2DM and established neuropathy, concomitant weight gain and hypoglycaemia, and the use of insensitive endpoints.^{17,18} Most of the studies assessing the effect of improved glycaemic control on neuropathy in T2DM were neither powered nor designed to show a benefit on neuropathy.¹⁶ Cardiovascular risk factors, especially hypertension and triglycerides have been shown to play an important role in the development of diabetic neuropathy.¹⁹ The STENO-2 study showed the overwhelming benefit of multifactorial risk factor reduction on cardiovascular outcomes,²⁰ mortality,²¹ retinopathy, nephropathy and autonomic neuropathy, but not somatic neuropathy, as vibration perception was the endpoint for assessing neuropathy.²² Indeed, a recent Japanese study has shown that intensive multifactorial intervention which led to an almost normalization of glycosylated haemoglobin (HbA1c) with weight loss and a reduction in blood pressure showed a significant improvement in neurophysiology and small-nerve-fibre repair, assessed using corneal confocal microscopy,²³ echoing the results of a previous study.²⁴ Early diagnosis and intervention may also be the key, as lifestyle intervention in patients with prediabetes improved sudomotor function and intraepidermal nerve-fibre density.²⁵ Indeed, smaller studies which have utilized more rigorous endpoints have shown a significant benefit on neurophysiology after treatment with an angiotensin-converting enzyme (ACE) inhibitor²⁶ and on neurological deficits and neurophysiology after treatment with an ACE inhibitor and calcium-channel blocker.²⁷ Statins or fibrates can also prevent the development of DPN,^{28,29} reduce diabetic

foot infection,³⁰ lower-extremity amputation^{31,32} and increase healing of foot ulcers.³³ A *post hoc* analysis of the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) study has shown that the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide reduced ulcer-related foot amputation.³⁴ There are compelling experimental data showing a direct benefit of GLP-1 agonists on neuropathy.^{35–37} This would suggest that the GLP-1 agonists may have potential benefits in the treatment of diabetic neuropathy³⁵ and a randomized clinical trial with rigorous endpoints is required to show this. The lack of rigorous and sensitive endpoints,⁴ recruitment of patients with a broad spectrum of neuropathy severity and short trial durations have contributed to the failure of clinical trials in DPN.¹⁷ Accurate phenotyping to select and stratify patients using sensitive endpoints targeting small-fibre repair (corneal confocal microscopy, skin biopsy) may allow trials of shorter duration to show an initial therapeutic effect. This would provide pharmaceutical companies with a go–no-go signal to invest in larger and longer trials, to gain US Food and Drug Administration (FDA) approval of disease-modifying therapies for DPN.¹⁸

Painful diabetic neuropathy

Painful diabetic neuropathy (PDN), a manifestation of small-fibre damage^{38–40} is characterized by burning pain and significantly impacts on the patient's quality of life,^{41–43} due to associated depression, anxiety and sleep disturbance.⁴² It can affect 14.0–65.3% of patients with diabetes,^{41,44–49} and the broad prevalence rates are attributed to different populations, risk factors and diagnostic methods. Paradoxically, the prevalence of painful symptoms may be higher in south Asians, despite a lower overall prevalence of neuropathy⁵⁰ and small-fibre neuropathy.⁵¹ Despite the availability of a number of questionnaires, for example, the Douleur Neuropathique 4 (DN4) questionnaire,⁵² Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale⁵³ and Neuropathic Pain Questionnaire (NPQ),⁵⁴ a large proportion of patients with PDN remain undiagnosed,^{55,56} and 'suffer in silence'.⁵⁷ The risk factors for painful diabetic neuropathy include older age, duration of diabetes, presence of diabetic peripheral neuropathy,^{41,44–46,48} obesity,^{41,45,56,58} smoking,^{44,58} poor glycaemic control,^{59,60} low high-density lipoprotein (HDL) cholesterol,⁴¹ elevated low-density lipoprotein (LDL) cholesterol, triglycerides and creatinine,⁴⁷ and vitamin D deficiency.^{61,62}

Treatment of PDN

There is no evidence that improvement in glycaemic control improves PDN; indeed, the opposite is true, where rapid and large reductions in HbA1c may precipitate an acute painful neuropathy.⁶³ The treatment of PDN has relied on trying different moderately effective therapies until one works, with minimal side effects. However, improved genotyping^{64,65} and clinical phenotyping⁶⁶ may allow targeted mechanism-based therapies. Identifying patients with an irritable nociceptor can reduce the number needed to treat (NNT) for oxcarbazepine to 3.9 compared with 6.9 in patients with the nonirritable nociceptor.⁶⁷ Similarly, identifying patients with altered rate-dependent depression (RDD), a marker of descending inhibitory pathway dysfunction, may focus on those who will respond optimally to selective norepinephrine-reuptake inhibitors, for example, duloxetine.⁶⁸

Tricyclic antidepressants (TCAs) mediate analgesic efficacy by indirectly modifying the opioid system in the brain and *via* neuromodulation of serotonin and noradrenaline.^{69–71} A systematic review of 17 studies involving amitriptyline in 1342 participants in PDN trials showed moderate efficacy and caution, as there was a high risk of bias due to the small participant numbers in each study.⁷² Duloxetine and venlafaxine potentiate the descending inhibitory pathways,⁷³ and a Cochrane review of eight randomized controlled trials (RCTs) with 2728 participants showed that duloxetine 60mg daily had an NNT of five.⁷⁴ Although gabapentin is not FDA approved for the treatment of PDN, a recent Cochrane review has shown efficacy of this medication in DPN and it is widely prescribed. However, somnolence and dizziness limit dose titration and most patients do not receive the doses (1200–3600mg) that have been shown to be efficacious.⁷⁵ Pregabalin is FDA approved for PDN, based on a number of RCTs.^{76–78} Mirogabalin has recently shown efficacy and good tolerability in a phase II and two phase III clinical trials in DPN.^{79–81} Tramadol may also be used second line, but a Cochrane review found that the efficacy of tramadol was determined in small inadequate-sized studies, with a risk of bias.⁸² Tapentadol extended release is only the third medication to be recommended by the FDA for PDN.^{83–86} The COMBO-DN study showed comparable neuropathic pain outcomes between a combination of duloxetine 60mg daily and pregabalin 300mg daily, compared with high-dose monotherapy of

Table 2. Symptoms and deficits in diabetic autonomic neuropathy.

Cardiac autonomic neuropathy	
Resting tachycardia and/or fixed HR	
Nondipping of nocturnal systolic BP	
Orthostatic hypotension	
Exercise intolerance	
Syncope and light headedness	
Painless myocardial infarction	
Arrhythmias	
Sudomotor neuropathy	
Anhidrosis	
Gustatory sweating	
Urogenital autonomic neuropathy	
Bladder dysfunction	
(1) Nocturnal frequency and urgency	
(2) Urinary hesitancy, weak stream, dribbling and urinary incontinence	
Sexual dysfunction	
Male: erectile dysfunction, decreased libido and retrograde ejaculation	
Female: decreased sexual desire and arousal, inadequate lubrication	
Gastrointestinal autonomic neuropathy	
Nausea/vomiting	
Bloating with inability to eat a full meal	
Increased variability in blood sugar and hypos	
Nocturnal diarrhoea	
BP, blood pressure; HR, heart rate.	

either duloxetine 120mg daily or pregabalin 600mg daily.⁸⁷ Furthermore, in an exploratory *post hoc* analysis, high-dose monotherapy was more favourable in patients with severe pain, whereas combination therapy was more beneficial in patients with mild-to-moderate pain.⁸⁸ There are few head-to-head studies comparing different drugs, but in a double-blind RCT in patients with PDN, analgesic efficacy was comparable between amitriptyline, duloxetine and pregabalin.⁸⁹ We have recently shown that treatment with vitamin D improves the severity of neuropathic pain⁹⁰ and quality of life in patients with PDN.⁹¹

Autonomic neuropathy

Autonomic neuropathy is characterized by a range of symptoms and signs, which can be debilitating in a minority of patients, especially females with T1DM (Table 2). Cardiac autonomic neuropathy (CAN) *per se* is the strongest risk factor for all-cause mortality in T1DM and was an independent risk factor for mortality in the ACCORD study of patients with T2DM.^{92,93} Hence, screening for CAN is recommended at diagnosis in T2DM and after 5 years in

T1DM.¹ The diagnosis of CAN includes documentation of the symptoms and signs, although there is a weak correlation between symptoms and autonomic deficits.^{94,95} Cardiovascular autonomic reflex testing (CARTs) includes heart rate response to deep breathing, standing and the Valsalva manoeuvre.⁹⁶

Disease-modifying therapies for autonomic neuropathy

The DCCT showed that intensive glycaemic control in patients with T1DM reduced the development of CAN by 45%.⁹⁷ and the STENO-2 trial showed that intensified multifactorial treatment in patients with type 2 diabetes reduced the risk of CAN progression by 68%.^{98,99} A small early study found favourable effects of alpha-lipoic acid (ALA) on CAN,¹⁰⁰ but a more recent study of triple antioxidant therapy (allopurinol, ALA and nicotinamide) showed no benefit.¹⁰¹ There are currently no FDA-approved disease-modifying treatments for CAN.

Orthostatic hypotension

Symptoms of orthostatic hypotension (OH) occur on standing and include light headedness, weakness, giddiness and syncope. OH is defined as a blood pressure fall on standing $>20/10$ mmHg ($>30/15$ mmHg in those with BP $>150/90$ mmHg) without an increase in heart rate (<15 beats per minute).¹⁰² Treatment of OH involves fluid and salt repletion and encouragement of physical activity and exercise to avoid deconditioning.^{103,104} Fludrocortisone is used but is not FDA approved for OH, and there are concerns over supine hypertension, hypokalaemia, congestive cardiac failure and peripheral oedema.¹⁰⁵ Both midodrine and droxidopa are approved by the FDA for the treatment of symptomatic neurogenic OH.¹⁰⁶

Gastroparesis

Gastroparesis may present with bloating, nausea and overt recurrent vomiting, necessitating admission to hospital, or may underlie unexplained variability in blood sugars. It is defined as the delayed removal of stomach contents in the absence of a physical obstruction.¹⁰⁷ Gastric emptying should be formally assessed at 15-min intervals, with scintigraphy 4h after food intake of digestible solids. Metoclopramide is the only FDA-approved drug for the treatment of gastroparesis, but limited efficacy and the risk of tardive dyskinesia has led the FDA and European

Medicines agency to limit its use to a maximum of 5 days. New therapies currently being investigated include motilin-receptor agonists, ghrelin-receptor agonists, and neurokinin-receptor antagonists. Mechanical options for intervention include transpyloric stenting, gastric electrical stimulation, and gastric per-oral endoscopic myotomy and in severe intractable gastroparesis, laparoscopic pyloroplasty or gastrectomy may be options.¹⁰⁸

Diabetic diarrhoea

Diarrhoea occurs twice as frequently in diabetic patients and of course may be related to pancreatic exocrine insufficiency, bariatric surgery, and drugs such as metformin and GLP-1 agonists.^{109,110} Pharmacological therapies include antibiotics to eradicate bacterial overgrowth, somatostatin analogues, and selective serotonin 5-hydroxy tryptamine type 3 (HT3) receptor antagonists.^{111,112}

Bladder dysfunction

Bladder dysfunction may occur in 50% of patients with diabetes due to urogenital autonomic neuropathy.¹¹³ Increased initiating threshold for the micturition reflex is followed by decreased detrusor activity and incomplete bladder emptying. The diagnosis should be based on urodynamic studies and the assessment of residual bladder volume. Treatment includes suprapubic pressure, intermittent self-catheterization, anticholinergic medication for detrusor hyperreflexia and parasympathomimetic medication to reduce detrusor contractility.¹¹⁴

Sudomotor dysfunction

A reduction or loss of distal sweating due to sympathetic denervation of the sweat glands is common^{115,116} and can precipitate a break in the skin, leading to foot ulceration. It can be assessed using neuropad®^{117–119} (Miro Verbandstoffe, Wiehl, Germany) or Sudoscan™¹²⁰ Impeto Medical, Paris, France to risk stratify patients with DPN.¹²¹

Erectile dysfunction

Erectile dysfunction (ED) in patients with diabetes is three times more prevalent, may occur 10–15 years earlier and is less responsive to treatment, compared to patients without diabetes.¹²² ED is associated with a higher HbA1c, presence of metabolic syndrome, hypertension, dyslipidaemia,

lower estimated glomerular filtration rate, higher albumin/creatinine ratio and more severe small-fibre neuropathy.^{123–125} Around 47% of women with diabetic neuropathy also have sexual dysfunction characterized by reduced sexual arousal, decreased lubrication and painful intercourse.¹²⁶ Recent recommendations include active smoking cessation (improves ED by ~30%), testosterone replacement in those with testosterone deficiency, statins, phosphodiesterase type 5 inhibitors, intra-cavernosal and transurethral prostaglandins, and penile implants for more severe cases.^{127–129}

Diabetic somatic and autonomic neuropathy have a significant impact on morbidity and mortality in the diabetic patient and yet remain woefully underdiagnosed and inadequately managed. Although there are currently no FDA-approved disease-modifying therapies, there is evidence that improvement in vascular risk factors alongside glycaemia may have a beneficial effect. Moderate relief of symptomatic, painful and autonomic neuropathy is possible, but requires early recognition and tailored intervention.

Acknowledgements

SA, MF, AK, HA, AAM, NH, SM, HB, HG, AK, GP, INP, UA contributed to the initial version of this article. RAM contributed and finalized the writing of the review.

Ethical Approval

Ethical approval was not required for this review.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

The authors declare that there is no conflict of interest.

ORCID iD

Rayaz A Malik  <https://orcid.org/0000-0002-7188-8903>

References

1. Pop-Busui R, Boulton AJ, Feldman EL, *et al.* Diabetic neuropathy: a position statement by the American Diabetes Association. *Diabetes Care* 2017; 40: 136–154.
2. Asghar O, Petropoulos IN, Alam U, *et al.* Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. *Diabetes Care* 2014; 37: 2643–2646.
3. Azmi S, Ferdousi M, Petropoulos IN, *et al.* Corneal confocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type 2 diabetes. *Diabetes Care* 2015; 38: 1502–1508.
4. Malik RA. Which test for diagnosing early human diabetic neuropathy? *Diabetes* 2014; 63: 2206–2208.
5. Martinelli-Boneschi F, Colombi M, Castori M, *et al.* COL6A5 variants in familial neuropathic chronic itch. *Brain* 2017; 140: 555–567.
6. Rajabally YA, Stettner M, Kieseier BC, *et al.* CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. *Nat Rev Neurol* 2017; 13: 599–611.
7. Alam U, Riley DR, Jugdey RS, *et al.* Diabetic neuropathy and gait: a review. *Diabetes Ther* 2017; 8: 1253–1264.
8. Almurudhi MM, Brown SJ, Bowling FL, *et al.* Altered walking strategy and increased unsteadiness in participants with impaired glucose tolerance and type 2 diabetes relates to small-fibre neuropathy but not vitamin D deficiency. *Diabet Med* 2017; 34: 839–845.
9. Almurudhi MM, Reeves ND, Bowling FL, *et al.* Reduced lower-limb muscle strength and volume in patients with type 2 diabetes in relation to neuropathy, intramuscular fat, and vitamin D levels. *Diabetes Care* 2016; 39: 441–447.
10. Yong TY and Khaw KSF. Diabetic muscle infarction in end-stage renal disease: a scoping review on epidemiology, diagnosis and treatment. *World J Nephrol* 2018; 7: 58–64.
11. Watanabe K, Hagura R, Akanuma Y, *et al.* characteristics of cranial nerve palsies in diabetic patients. *Diabetes Res Clin Pract* 1990; 10: 19–27.
12. Calandruccio JH and Thompson NB. Carpal tunnel syndrome: making evidence-based treatment decisions. *Orthop Clin North Am* 2018; 49: 223–229.
13. Mojaddidi MA, Ahmed MS, Ali R, *et al.* Molecular and pathological studies in the posterior interosseous nerve of diabetic and non-diabetic patients with carpal tunnel syndrome. *Diabetologia* 2014; 57: 1711–1719.
14. Thomsen NO, Mojaddidi M, Malik RA, *et al.* Reduced myelinated nerve fibre and

- endoneurial capillary densities in the forearm of diabetic and non-diabetic patients with carpal tunnel syndrome. *Acta Neuropathol* 2009; 118: 785–791.
15. Thomsen NOB, Andersson GS, Bjork J, *et al.* Neurophysiological recovery 5 years after carpal tunnel release in patients with diabetes. *Muscle Nerve* 2017; 56: E59–E64.
 16. Callaghan BC, Little AA, Feldman EL, *et al.* Enhanced glucose control for preventing and treating diabetic neuropathy. *Cochrane Database Syst Rev* 2012; 6: CD007543.
 17. Malik RA. Why are there no good treatments for diabetic neuropathy? *Lancet Diabetes Endocrinol* 2014; 2: 607–609.
 18. Malik RA. Wherefore art thou, o treatment for diabetic neuropathy? *Int Rev Neurobiol* 2016; 127: 287–317.
 19. Tesfaye S, Chaturvedi N, Eaton SE, *et al.* Vascular risk factors and diabetic neuropathy. *N Engl J Med* 2005; 352: 341–350.
 20. Oellgaard J, Gaede P, Rossing P, *et al.* Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised STENO-2 study. *Diabetologia* 2018; 61: 1724–1733.
 21. Gaede P, Lund-Andersen H, Parving HH, *et al.* Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008; 358: 580–591.
 22. Gaede P, Vedel P, Larsen N, *et al.* Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003; 348: 383–393.
 23. Ishibashi F, Taniguchi M, Kosaka A, *et al.* Improvement in neuropathy outcomes with normalizing HbA1c in patients with type 2 diabetes. *Diabetes Care*. Epub ahead of print 19 November 2018. DOI: 10.2337/dc18-1560.
 24. Tavakoli M, Kallinikos P, Iqbal A, *et al.* Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. *Diabet Med* 2011; 28: 1261–1267.
 25. Smith AG, Russell J, Feldman EL, *et al.* Lifestyle intervention for pre-diabetic neuropathy. *Diabetes Care* 2006; 29: 1294–1299.
 26. Malik RA, Williamson S, Abbott C, *et al.* Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. *Lancet* 1998; 352: 1978–1981.
 27. Ruggenenti P, Lauria G, Iliev IP, *et al.* Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. *Hypertension* 2011; 58: 776–783.
 28. Nielsen SF and Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. *Lancet Diabetes Endocrinol* 2014; 2: 894–900.
 29. Davis TM, Yeap BB, Davis WA, *et al.* Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. *Diabetologia* 2008; 51: 562–566.
 30. Nassaji M, Ghorbani R and Saboori Shkofte H. Previous atorvastatin treatment and risk of diabetic foot infection in adult patients: a case-control study. *Wounds* 2017; 29: 196–201.
 31. Rajamani K, Colman PG, Li LP, *et al.* Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. *Lancet* 2009; 373: 1780–1788.
 32. Sohn MW, Meadows JL, Oh EH, *et al.* Statin use and lower extremity amputation risk in nonelderly diabetic patients. *J Vasc Surg* 2013; 58: 1578–1585.e1.
 33. Fox JD, Baquerizo-Nole KL, Macquhae F, *et al.* Statins may be associated with six-week diabetic foot ulcer healing. *Wound Repair Regen* 2016; 24: 454–457.
 34. Dhatariya K, Bain SC, Buse JB, *et al.* The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. *Diabetes Care* 2018; 41: 2229–2235.
 35. Moustafa PE. Liraglutide ameliorated peripheral neuropathy in diabetic rats: involvement of oxidative stress, inflammation and extracellular matrix remodeling. *Diabetes Metab Res Rev* 2018; 146: 173–185.
 36. Sango K and Utsunomiya K. Efficacy of glucagon-like peptide-1 mimetics for neural regeneration. *Neural Regen Res* 2015; 10: 1723–1724.
 37. Tsukamoto M, Niimi N, Sango K, *et al.* Neurotrophic and neuroprotective properties

- of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA. *Histochem Cell Biol* 2015; 144: 249–259.
38. Sorensen L, Molyneaux L and Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. *Diabetes Care* 2006; 29: 883–887.
 39. Vlckova-Moravcova E, Bednarik J, Belobradkova J, *et al.* Small-fibre involvement in diabetic patients with neuropathic foot pain. *Diabet Med* 2008; 25: 692–699.
 40. Quattrini C, Tavakoli M, Jeziorska M, *et al.* Surrogate markers of small fiber damage in human diabetic neuropathy. *Diabetes* 2007; 56: 2148–2154.
 41. Van Acker K, Bouhassira D, De Bacquer D, *et al.* Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. *Diabetes Metab* 2009; 35: 206–213.
 42. Bohlega S, Alsaadi T, Amir A, *et al.* Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the middle East region. *J Int Med Res* 2010; 38: 295–317.
 43. DaCosta DiBonaventura M, Cappelleri JC and Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. *Pain Med* 2011; 12: 118–126.
 44. Abbott CA, Malik RA, van Ross ER, *et al.* Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. *Diabetes Care* 2011; 34: 2220–2224.
 45. Jambart S, Ammache Z, Haddad F, *et al.* Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. *J Int Med Res* 2011; 39: 366–377.
 46. Davies M, Brophy S, Williams R, *et al.* The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. *Diabetes Care* 2006; 29: 1518–1522.
 47. Ziegler D, Rathmann W, Meisinger C, *et al.* Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. *Eur J Pain* 2009; 13: 582–587.
 48. Jacovides A, Bogoshi M, Distiller LA, *et al.* An epidemiological study to assess the prevalence of diabetic peripheral neuropathic pain among adults with diabetes attending private and institutional outpatient clinics in South Africa. *J Int Med Res* 2014; 42: 1018–1028.
 49. Sadosky A, McDermott AM, Brandenburg NA, *et al.* A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. *Pain Pract* 2008; 8: 45–56.
 50. Abbott CA, Chaturvedi N, Malik RA, *et al.* Explanations for the lower rates of diabetic neuropathy in Indian Asians versus Europeans. *Diabetes Care* 2010; 33: 1325–1330.
 51. Fadavi H, Tavakoli M, Foden P, *et al.* Explanations for less small fibre neuropathy in south Asian versus European subjects with type 2 diabetes in the UK. *Diabetes Metab Res Rev* 2018; 34: e3044.
 52. Spallone V, Morganti R, D’Amato C, *et al.* Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. *Diabet Med* 2012; 29: 578–585.
 53. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. *Pain* 2001; 92: 147–157.
 54. Krause SJ and Backonja MM. Development of a neuropathic pain questionnaire. *Clin J Pain* 2003; 19: 306–314.
 55. Daousi C, MacFarlane IA, Woodward A, *et al.* Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. *Diabet Med* 2004; 21: 976–982.
 56. Ziegler D, Landgraf R, Lobmann R, *et al.* Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). *Diabetes Res Clin Pract* 2018; 139: 147–154.
 57. Malik RA, Aldinc E, Chan SP, *et al.* Perceptions of painful diabetic peripheral neuropathy in South-East Asia: results from patient and physician surveys. *Adv Ther* 2017; 34: 1426–1437.
 58. Aslam A, Singh J and Rajbhandari S. Prevalence of painful diabetic neuropathy using the self-completed Leeds assessment of neuropathic symptoms and signs questionnaire in a population with diabetes. *Can J Diabetes* 2015; 39: 285–295.
 59. Harris M, Eastman R and Cowie C. Symptoms of sensory neuropathy in adults with NIDDM

- in the U.S. population. *Diabetes Care* 1993; 16: 1446–1452.
60. Smith AG and Singleton JR. Impaired glucose tolerance and neuropathy. *Neurologist* 2008; 14: 23–29.
 61. Alam U, Arul-Devah V, Javed S, *et al.* Vitamin D and diabetic complications: true or false prophet? *Diabetes Ther* 2016; 7: 11–26.
 62. Shillo P, Selvarajah D, Greig M, *et al.* Reduced vitamin D levels in painful diabetic peripheral neuropathy. Epub ahead of print 20 September 2018. DOI: 10.1111/dme.13798.
 63. Gibbons CH and Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. *Brain* 2015; 138: 43–52.
 64. Spallone V. Might genetics play a role in understanding and treating diabetic polyneuropathy? *Diabetes Metab Res Rev* 2017; 33.
 65. Wadhawan S, Pant S, Golhar R, *et al.* NaV channel variants in patients with painful and nonpainful peripheral neuropathy. *Neurol Genet* 2017; 3: e207.
 66. Vollert J, Maier C, Attal N, *et al.* Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. *Pain* 2017; 158: 1446–1455.
 67. Demant DT, Lund K, Vollert J, *et al.* The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. *Pain* 2014; 155: 2263–2273.
 68. Marshall AG, Lee-Kubli C, Azmi S, *et al.* Spinal disinhibition in experimental and clinical painful diabetic neuropathy. *Diabetes* 2017; 66: 1380–1390.
 69. Botney M and Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. *Ann Neurol* 1983; 13: 160–164.
 70. Benbouzid M, Gaveriaux-Ruff C, Yalcin I, *et al.* Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. *Biol Psychiatry* 2008; 63: 633–636.
 71. De Gandarias JM, Echevarria E, Acebes I, *et al.* Effects of imipramine administration on mu-opioid receptor immunostaining in the rat forebrain. *Arzneimittelforschung* 1998; 48: 717–719.
 72. Moore RA, Derry S, Aldington D, *et al.* Amitriptyline for neuropathic pain in adults. *Cochrane Database Syst Rev* 2015; 7: CD008242.
 73. Hossain SM, Hussain SM and Ekram AR. Duloxetine in painful diabetic neuropathy: a systematic review. *Clin J Pain* 2016; 32: 1005–1010.
 74. Lunn MP, Hughes RA and Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. *Cochrane Database Syst Rev* 2014; 3: CD007115.
 75. Wiffen PJ, Derry S, Bell RF, *et al.* Gabapentin for chronic neuropathic pain in adults. *Cochrane Database Syst Rev* 2017; 6: CD007938.
 76. Lesser H, Sharma U, LaMoreaux L, *et al.* Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. *Neurology* 2004; 63: 2104–2110.
 77. Rosenstock J, Tuchman M, LaMoreaux L, *et al.* Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. *Pain* 2004; 110: 628–638.
 78. Arezzo JC, Rosenstock J, Lamoreaux L, *et al.* Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. *BMC Neurol* 2008; 8: 33.
 79. Javed S, Alam U and Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. *J Pain Res* 2018; 11: 1559–1566.
 80. Merante D, Rosenstock J, Sharma U, *et al.* Efficacy of mirogabalin (DS-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase II proof-of-concept study. *Pain Med* 2017; 18: 2198–2207.
 81. Vinik A, Rosenstock J, Sharma U, *et al.* Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. *Diabetes Care* 2014; 37: 3253–3261.
 82. Duehmke RM, Derry S, Wiffen PJ, *et al.* Tramadol for neuropathic pain in adults. *Cochrane Database Syst Rev* 2017; 15: CD003726.
 83. Vinik AI, Shapiro DY, Rauschkolb C, *et al.* A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. *Diabetes Care* 2014; 37: 2302–2309.
 84. Niesters M, Proto PL, Aarts L, *et al.* Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic

- polyneuropathy. *Br J Anaesth* 2014; 113: 148–156.
85. Schwartz S, Etropolski MS, Shapiro DY, *et al.* A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. *Clin Drug Investig* 2015; 35: 95–108.
 86. Vadivelu N, Kai A, Maslin B, *et al.* Tapentadol extended release in the management of peripheral diabetic neuropathic pain. *Ther Clin Risk Manag* 2015; 11: 95–105.
 87. Tesfaye S, Wilhelm S, Lledo A, *et al.* Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”—a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. *Pain* 2013; 154: 2616–2625.
 88. Bouhassira D, Wilhelm S, Schacht A, *et al.* Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. *Pain* 2014; 155: 2171–2179.
 89. Boyle J, Eriksson MEV, Gribble L, *et al.* Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. *Diabetes Care* 2012; 35: 2451–2458.
 90. Basit A, Basit KA, Fawwad A, *et al.* Vitamin D for the treatment of painful diabetic neuropathy. *BMJ Open Diabetes Res Care* 2016; 4: e000148.
 91. Alam U and Fawwad A. Improvement in neuropathy specific quality of life in patients with diabetes after vitamin D supplementation. *J Diabetes Res* 2017; 2017: 7928083.
 92. Soedamah-Muthu SS, Chaturvedi N, Witte DR, *et al.* Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). *Diabetes Care* 2008; 31: 1360–1366.
 93. Pop-Busui R, Evans GW, Gerstein HC, *et al.* Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Diabetes Care* 2010; 33: 1578–1584.
 94. Low PA, Benrud-Larson LM, Sletten DM, *et al.* Autonomic symptoms and diabetic neuropathy: a population-based study. *Diabetes Care* 2004; 27: 2942–2947.
 95. Suarez GA, Opfer-Gehrking TL, Offord KP, *et al.* The autonomic symptom profile: a new instrument to assess autonomic symptoms. *Neurology* 1999; 52: 523–528.
 96. Tesfaye S, Boulton AJ, Dyck PJ, *et al.* Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care* 2010; 33: 2285–2293.
 97. Martin CL, Albers JW, Pop-Busui R, *et al.* Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. *Diabetes Care* 2014; 37: 31–38.
 98. Charles M, Fleischer J, Witte DR, *et al.* Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. *Diabetologia* 2013; 56: 101–108.
 99. Charles M, Ejskjaer N, Witte DR, *et al.* Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. *Diabetes Care* 2011; 34: 2244–2249.
 100. Ziegler D, Schatz H, Conrad F, *et al.* Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). *Deutsche Kardiale Autonome Neuropathie. Diabetes Care* 1997; 20: 369–373.
 101. Pop-Busui R, Stevens MJ, Raffel DM, *et al.* Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. *Diabetologia* 2013; 56: 1835–1844.
 102. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. *Diabetes Care* 2010; 33: 434–441.
 103. Freeman R, Abuzinadah AR, Gibbons C, *et al.* Orthostatic hypotension: JACC state-of-the-art review. *J Am Coll Cardiol* 2018; 72: 1294–1309.
 104. Gibbons CH, Schmidt P, Biaggioni I, *et al.* The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. *J Neurol* 2017; 264: 1567–1582.
 105. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. *N Engl J Med* 2008; 358: 615–624.

106. Kaufmann H. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn? *Clin Auton Res* 2017; 27: 1–3.
107. Parkman HP, Hasler WL, Fisher RS, *et al.* American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. *Gastroenterology* 2004; 127: 1592–1622.
108. Kumar M, Chapman A, Javed S, *et al.* The investigation and treatment of diabetic gastroparesis. *Clin Ther* 2018; 40: 850–861.
109. Sommers T, Mitsuhashi S, Singh P, *et al.* Prevalence of chronic constipation and chronic diarrhea in diabetic individuals in the United States. *Am J Gastroenterol.* 2019; 114: 135–142.
110. Borbely YM, Osterwalder A, Kroll D, *et al.* Diarrhea after bariatric procedures: diagnosis and therapy. *World J Gastroenterol* 2017; 23: 4689–4700.
111. Murao S and Hosokawa H. Serotonin 5-HT₃ receptor antagonist for treatment of severe diabetic diarrhea. *Diabetes Care* 2010; 33: e38.
112. Ogonnaya KI and Arem R. Diabetic diarrhea. Pathophysiology, diagnosis, and management. *Arch Intern Med* 1990; 150: 262–267.
113. Freeman R. Autonomic peripheral neuropathy. *Lancet* 2005; 365: 1259–1270.
114. Yuan Z, Tang Z, He C, *et al.* Diabetic cystopathy: a review. *J Diabetes* 2015; 7: 442–447.
115. Gibbons CH, Illigens BM, Wang N, *et al.* Quantification of sweat gland innervation: a clinical-pathologic correlation. *Neurology* 2009; 72: 1479–1486.
116. Gibbons CH, Illigens BM, Wang N, *et al.* Quantification of sudomotor innervation: a comparison of three methods. *Muscle Nerve* 2010; 42: 112–119.
117. Ponirakis G, Fadavi H, Petropoulos IN, *et al.* Automated quantification of neuropad improves its diagnostic ability in patients with diabetic neuropathy. *J Diabetes Res* 2015; 2015: 847854.
118. Ponirakis G, Petropoulos IN, Fadavi H, *et al.* The diagnostic accuracy of neuropad for assessing large and small fibre diabetic neuropathy. *Diabet Med* 2014; 31: 1673–1680.
119. Quattrini C, Jeziorska M, Tavakoli M, *et al.* The neuropad test: a visual indicator test for human diabetic neuropathy. *Diabetologia* 2008; 51: 1046–1050.
120. Krieger SM, Reimann M, Haase R, *et al.* Sudomotor testing of diabetes polyneuropathy. *Front Neurol* 2018; 9: 803.
121. Tsapas A, Liakos A, Paschos P, *et al.* A simple plaster for screening for diabetic neuropathy: a diagnostic test accuracy systematic review and meta-analysis. *Metabolism* 2014; 63: 584–592.
122. Feldman HA, Goldstein I, Hatzichristou DG, *et al.* Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. *J Urol* 1994; 151: 54–61.
123. Azmi S, Ferdousi M, Alam U, *et al.* Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. *Diabetologia* 2017; 60: 1094–1101.
124. Giugliano F, Maiorino M, Bellastella G, *et al.* Determinants of erectile dysfunction in type 2 diabetes. *Int J Impot Res* 2010; 22: 204.
125. Van Den Eeden SK, Sarma AV, Rutledge BN, *et al.* Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. *Diabetes Care* 2009; 32: 664–670.
126. Enzlin P, Mathieu C, Van den Bruel A, *et al.* Sexual dysfunction in women with type 1 diabetes: a controlled study. *Diabetes Care* 2002; 25: 672–677.
127. Hackett G, Kirby M, Wylie K, *et al.* British Society for Sexual Medicine guidelines on the management of erectile dysfunction in men-2017. *J Sex Med* 2018; 15: 430–457.
128. Mulhall JP, Giraldi A, Hackett G, *et al.* The 2018 revision to the process of care model for evaluation of erectile dysfunction. *J Sex Med* 2018; 15: 1280–1292.
129. Mulhall JP, Giraldi A, Hackett G, *et al.* The 2018 revision to the process of care model for management of erectile dysfunction. *J Sex Med* 2018; 15: 1434–1445.